MXPA05010804A - Torio 227 para uso en radioterapia de enfermedades del tejido blando. - Google Patents

Torio 227 para uso en radioterapia de enfermedades del tejido blando.

Info

Publication number
MXPA05010804A
MXPA05010804A MXPA05010804A MXPA05010804A MXPA05010804A MX PA05010804 A MXPA05010804 A MX PA05010804A MX PA05010804 A MXPA05010804 A MX PA05010804A MX PA05010804 A MXPA05010804 A MX PA05010804A MX PA05010804 A MXPA05010804 A MX PA05010804A
Authority
MX
Mexico
Prior art keywords
thorium
soft tissue
tissue disease
radiotherapy
subject
Prior art date
Application number
MXPA05010804A
Other languages
English (en)
Inventor
Oyvind Bruland
Original Assignee
Algeta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by Algeta As filed Critical Algeta As
Publication of MXPA05010804A publication Critical patent/MXPA05010804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion proporciona un metodo para el tratamiento de una enfermedad del tejido blando en un sujeto mamifero (preferentemente un sujeto humano o canino), el metodo comprende administrar al sujeto una cantidad terapeuticamente efectiva de un complejo dirigido al tejido blando de torio 227 y un agente formador de un complejo, en donde la cantidad es tal que una cantidad aceptablemente no mielotoxica de radio 223 sea generada in vivo por la desintegracion nuclear del torio 227 administrado.
MXPA05010804A 2003-04-15 2004-04-15 Torio 227 para uso en radioterapia de enfermedades del tejido blando. MXPA05010804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy
PCT/GB2004/001654 WO2004091668A1 (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Publications (1)

Publication Number Publication Date
MXPA05010804A true MXPA05010804A (es) 2006-03-09

Family

ID=35385222

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010804A MXPA05010804A (es) 2003-04-15 2004-04-15 Torio 227 para uso en radioterapia de enfermedades del tejido blando.

Country Status (19)

Country Link
EP (1) EP1617876B1 (es)
JP (2) JP5006032B2 (es)
KR (2) KR101274867B1 (es)
CN (1) CN100586484C (es)
AU (1) AU2004229218B2 (es)
BR (1) BRPI0409387B8 (es)
CA (1) CA2522148C (es)
CY (1) CY1115407T1 (es)
DK (1) DK1617876T3 (es)
EA (1) EA008195B1 (es)
ES (1) ES2486845T3 (es)
HK (1) HK1094150A1 (es)
IL (1) IL171148A (es)
MX (1) MXPA05010804A (es)
NO (1) NO332931B1 (es)
NZ (3) NZ543044A (es)
PL (1) PL1617876T3 (es)
PT (1) PT1617876E (es)
ZA (1) ZA200507983B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507983B (en) * 2003-04-15 2007-03-28 Algetaas Thorium-227 for use in radiotherapy of soft tissue disease
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
EP3554257B1 (en) 2016-12-15 2023-07-12 Société des Produits Nestlé S.A. Compositions and methods that modulate white blood cells or neutrophils in a companion animal
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053196T3 (es) * 1989-06-19 1994-07-16 Akzo Nv Metodo para la produccion de un radioinmunoconjugado.
WO1993020852A2 (en) * 1992-04-13 1993-10-28 The Dow Chemical Company Macrocyclic chelating agents, chelates and conjugates thereof
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
CA2381123C (en) * 2000-02-25 2011-10-04 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
ZA200507983B (en) * 2003-04-15 2007-03-28 Algetaas Thorium-227 for use in radiotherapy of soft tissue disease

Also Published As

Publication number Publication date
NO332931B1 (no) 2013-02-04
EP1617876B1 (en) 2014-05-14
NO20055390D0 (no) 2005-11-15
BRPI0409387A (pt) 2006-04-18
DK1617876T3 (da) 2014-07-21
ZA200507983B (en) 2007-03-28
JP5468597B2 (ja) 2014-04-09
EA008195B1 (ru) 2007-04-27
AU2004229218B2 (en) 2009-05-07
CY1115407T1 (el) 2017-01-04
NZ543044A (en) 2010-04-30
EP1617876A1 (en) 2006-01-25
CA2522148A1 (en) 2004-10-28
CA2522148C (en) 2010-07-13
JP2012051942A (ja) 2012-03-15
CN1805760A (zh) 2006-07-19
NZ595758A (en) 2013-02-22
NO20055390L (no) 2006-01-16
AU2004229218A1 (en) 2004-10-28
CN100586484C (zh) 2010-02-03
KR20060015507A (ko) 2006-02-17
HK1094150A1 (en) 2007-03-23
KR20110022743A (ko) 2011-03-07
KR101274867B1 (ko) 2013-06-13
EA200501456A1 (ru) 2006-06-30
IL171148A (en) 2013-12-31
PL1617876T3 (pl) 2015-03-31
JP2006523664A (ja) 2006-10-19
BRPI0409387B8 (pt) 2021-05-25
ES2486845T3 (es) 2014-08-19
BRPI0409387B1 (pt) 2021-05-11
NZ606996A (en) 2014-08-29
PT1617876E (pt) 2014-08-04
JP5006032B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
DE60331933D1 (de) Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren
DE60113683D1 (en) Radiotherapy
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
Jeffcoat et al. Intrapocket anesthesia for scaling and root planing: results of a double‐blind multicenter trial using lidocaine prilocaine dental gel
TW200509968A (en) Prevention and treatment of synucleinopathic disease
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
MXPA03005394A (es) Composiciones que contienen complejos de inclusion.
EP1420716A4 (en) IMPLANTABLE AND SEALABLE SYSTEM FOR THE UNIDIRECTIONAL DISTRIBUTION OF THERAPEUTIC AGENTS OF TARGET TISSUE
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
TW200630089A (en) Treatment methods
HUP0401903A2 (hu) Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére
IL182352A0 (en) The use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
PT1677806E (pt) Métodos para tratamento de entorse e distensão muscular aguda e por excesso de esforço utilizando ácido hialurónico
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
AP1896A (en) The method of treating cancer
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
IL164092A0 (en) The use of devazepide as analgesic agent
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen

Legal Events

Date Code Title Description
FG Grant or registration